TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00482833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: idarubicin
Description: Induction~Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .~If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.~Consolidation~1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.~3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine
Description: Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: all-trans retinoic acid
Description: Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.~Consolidation~1. st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~2. nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~3. rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.~Maintenance therapy~ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid (ATRA)
Description: Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.~Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26).
Study: NCT04491058

Intervention type: DIAGNOSTIC_TEST
Intervention: SSCT thickness measurement
Description: Thickness measurement with ultrasound

Intervention type: DIAGNOSTIC_TEST
Intervention: SSCT thickness measurement
Description: Thickness measurement with ultrasound
Study: NCT01352039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin Sodium - Eurofarma
Description: Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium - APP Pharmaceuticals
Description: Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
Study: NCT00858286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spirometry, PEF measurements and diary cards to evaluate control of Asthma
Description: No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
Study: NCT01743547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
Study: NCT00851591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenugreek
Description: 3 capsules 3 times per day with a full glass of water each dose for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Psyllium)
Description: 3 capsules 3 times a day with a full glass of water each dose for 7 days
Study: NCT03655431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Participants complete a standard physical therapy evaluation in-person. They are then provided telerehabilitation equipment for the telerehabilitation intervention. This intervention utilizes an Xbox Kinect sensor and tablet-based exercise software called Jintronix. The Jintronix exercise library includes an array of exercise activity options for varying functional levels. Exercise activities could be completed in sitting or standing postures and includes activities which focused on active range of motion, strength, balance, or calisthenic movements. Each activity requires the participant to complete a goal-directed game or replicate movements of an on-screen avatar. The therapist will adjust and progress the home exercise program using information provided by the Jintronix and the participant's verbal reports during clinical video teleconferencing. At the end of the intervention, the therapist will complete in-person discharge assessments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Participants complete standard in-person physical therapy evaluation, follow-up, and treatment. Therapeutic exercise and activities will be prescribed to participants to perform at home between standard follow-up treatment appointments. At the end of the intervention, the physical therapist will complete in-person discharge assessments.
Study: NCT01202448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSF analysis
Description: The cerebrospinal fluid will be evaluated via lumbar puncture.
Study: NCT01727271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b
Study: NCT00360360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin AUC 6.0 IV Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab 15mg/kg IV infusion,Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib 150 mg by mouth daily
Study: NCT01318499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%
Description: Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension, 0.1%
Description: Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac Vehicle 0.3%
Description: Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
Study: NCT03693430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks
Study: NCT01066806

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: counseling on increasing calcium intake
Description: The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observation
Description: observe normal dairy intake
Study: NCT03039478

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol 7g
Description: Xylitol 7g in 300mL tap water
Study: NCT02042716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnosis of white matter damage in preterm infants
Description: Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
Study: NCT01536067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Given IV
Study: NCT00455351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Increasing dosing, phase I
Study: NCT00849459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus-mediated human interleukin-12
Description: The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/~1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC.
Study: NCT00945165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Description: various exercise characteristics

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No exercise
Description: No exercise control period
Study: NCT03039478

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol 10g
Description: Erythritol 10g in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol 17g
Description: Xylitol 17g in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol 35g
Description: Xylitol 35g in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol 25g
Description: Erythritol 25g in 300mL tap water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Erythritol 50g
Description: Erythritol 50g in 300mL tap water
Study: NCT01536067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01856933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: 2.5 mg/kg, IV, over 60 minutes every 3 weeks
Study: NCT03047252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation with a digital biofeedback system
Description: The system will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:~STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Home-based rehabilitation
Description: Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:~STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application
Study: NCT02593240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food
Description: The intensive iDiet® group behavioral weight loss program will be delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the iDiet® intervention will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher
Description: The intensive iDiet® group behavioral weight loss program delivered in person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Half of the participants per worksite receiving the Diet® intervention will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human Performance Institute©
Description: The Human Performance Institute© (HPI) training workshop is a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
Study: NCT01582347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6300
Description: Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).~Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subutex®/Suboxone®
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.
Study: NCT01054534

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placement of interstim lead
Description: Placement of insterstim lead using US image fusion technology
Study: NCT04228744

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS system
Description: The DBS device utilized in the present study includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead contains four stimulating contacts. The length of each contact is 1.5 mm, and the spacing between contacts is 1.5 mm.~The participants will receive stepwise surgery. The electrodes will be implanted firstly which will be externalized for several days and then the IPG will be implanted. During externalization, the experimenters will record the local field potential and electroencephalography in resting or task-based state with conditions of sham-stimulation or active-stimulation.
Study: NCT01582347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subutex®/Suboxone®
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.~Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for RBP-6300
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for RBP-6300
Description: Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.~Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Subutex®/Suboxone®
Description: Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
Study: NCT02453048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Intranasal live, attenuated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Intranasal live, attenuated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Intranasal live, attenuated vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPZE1
Description: Intranasal live, attenuated vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diluent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diluent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Diluent
Study: NCT04358523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC18
Description: ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir and sofosbuvir
Description: RDV 200 mg and SOF 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ravidasvir and sofosbuvir
Description: RDV 200 mg and SOF 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC18
Description: ASC18：ravidasvir and sofosbuvir fixed Dose Combination 200 mg/400 mg
Study: NCT02576496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Study: NCT03282864

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Bedroom air filtered by an air filtration device to remove airborne pollutants
Description: The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bedroom air filtered by an air filtration device to remove airborne pollutants
Description: The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.